Growth hormone support
Black Week
20% off everything with code BLACK
Click and the code is added to your cart.
Until Monday 30 Nov, 23:59 (Polish time).
Black Friday
20% off everything with code BLACK
Click and the code is added to your cart.
Until Monday 30 Nov, 23:59 (Polish time).
Last day
20% off everything with code BLACK
The code works until 23:59 today (Polish time).
Other categories
23 products
-
PEG-MGF 5mg PEG-MGF 5mg35,99 €
-
-
-
S-23 60 caps S-23 60 caps47,99 €
-
S4 60 caps S4 60 caps37,99 €
-
-
Growth hormone-boosting peptides – research reagents for GH secretion models (RUO)
The Endogenic line peptides collected here do not supply growth hormone (GH) from outside. In the preclinical literature they have been studied in models of GH secretion: stimulating the pituitary’s endogenous release of the hormone via GHRH receptors and the ghrelin receptor. They are reagents for studying the regulation of the somatotropic axis, and the category name describes the research direction. In line with Research Use Only principles, the text describes what a molecule does in a cellular or animal model, not what it “will do” in a human.
The stimulation follows two different routes: via the GHRH receptor and via the ghrelin receptor GHS-R. The two axes amplify each other’s action, so studies often pair a GHRH analogue with a ghrelin peptide. They also share a regulatory status: peptide GH-releasing factors and secretagogues fall under section S2 of the WADA list.
Compound families in this category
The category covers two mechanistic families studied in models of somatotropic axis stimulation.
GHRH analogues (growth hormone-releasing hormone)
These molecules mimic endogenous GHRH and stimulate the GHRH receptor on the pituitary somatotroph cells. Typical representatives are CJC-1295 with DAC, with an extended half-life, and CJC-1295 without DAC (Mod-GRF 1-29), with a short duration of action. The family also includes the research analogues Sermorelin and Tesamorelin. Tesamorelin has a counterpart authorised as a medicine (Egrifta®).
Ghrelin peptides (GHRPs): GHS-R agonists
These molecules mimic ghrelin and stimulate the GHS-R1a receptor. Typical representatives are Ipamorelin (a selective ghrelin mimetic), GHRP-2 (pralmorelin) and GHRP-6, and the family also includes the research compound Hexarelin. In models, a GHRH analogue is combined with a ghrelin peptide so that the two routes of somatotropic axis stimulation reinforce each other. This mechanism appears, among other areas, in research on muscle anabolism and tissue regeneration.
Regulatory status
Peptide growth hormone-releasing factors (GHRH analogues) and ghrelin secretagogues (GHRPs) fall under section S2 of the WADA list, subsection S2.2: peptide hormones and their releasing factors. Tesamorelin is authorised as the medicine Egrifta® for reducing excess visceral fat in HIV-associated lipodystrophy. The medicine and the reagent are separate regulatory entities. A research reagent with this sequence is not a substitute for the medicine, is not for treatment and does not replace medical consultation. The duty to check the current list of prohibited substances before any decision rests with athletes registered in the ADAMS system.
Applications in scientific research
Reagents from this category are used in work on the regulation of the somatotropic axis. The category gives no doses or schedules, because working concentrations and the route of administration are chosen by the researcher according to the protocol methodology. The main research directions:
- GHRH receptor pharmacology: affinity and functional profile of analogues in recombinant expression systems
- Agonism at the ghrelin receptor GHS-R1a: GH secretion and the selectivity of ghrelin mimetics in cellular models
- GHRH + GHRP synergy: pulsatile GH release in animal models with combined stimulation of both axes
- The GH/IGF-1 axis, metabolism and regeneration: secondary IGF-1 production in the liver and its role in body composition models
- Batch identity and purity: confirmation of sequence and mass by MS, HPLC purity determination and verification in the batch COA
Scientific perspective
The observations attributed to these peptides come from cellular and animal models. “Stimulation of GH secretion” means a result in a research model here, not a guaranteed effect in a person using the reagent. Endogenous GH secretion is subject to complex feedback regulation (somatostatin, IGF-1), so data from isolated models do not translate directly to human physiology.
Important distinction
No reagent in this category is a product for recovery, rejuvenation or “raising GH” in humans. Advertising slogans such as “a recovery peptide”, “a growth hormone jab” or “GH rejuvenation” cannot be reconciled with RUO principles.
Forms available in this category
Secretagogue peptides come in this category in forms that differ in how much preparation they need before work:
- Vial with lyophilisate: a dry form for the researcher to reconstitute. The researcher selects the solvent and working concentration, and this form offers the longest storage stability
- Single-vial mixture (blend): a co-lyophilised combination of a GHRH analogue and a ghrelin peptide, prepared for studies of combined stimulation of both axes. The identity of each component is confirmed by its sequence and mass in the batch COA
Because the GH/IGF-1 axis links growth hormone secretion with metabolism and regeneration, the category sits thematically next to reagents for muscle anabolism models.
Frequently asked questions (FAQ)
Do the peptides in this category boost growth hormone in humans?
This category makes no such claim. In preclinical models these peptides stimulate GH secretion via the GHRH receptor and the ghrelin receptor, but the description concerns results in models, not an effect in humans. RUO material is neither a medicine nor a recovery product.
How does the Tesamorelin reagent differ from the medicine Egrifta®?
In regulatory status and intended purpose. Tesamorelin is authorised as the medicine Egrifta® for a specific clinical indication and requires medical supervision. A research reagent with this sequence is a Research Use Only material and not a substitute for the medicine.
What is the difference between CJC-1295 with DAC and without DAC?
Mainly the time profile of action in models. The DAC (Drug Affinity Complex) variant binds to albumin and has a much longer half-life, while the variant without DAC (Mod-GRF 1-29) acts briefly and in pulses. Only the batch COA settles which variant it is, because the name alone does not determine the structure.
How can the identity of an ordered reagent be confirmed?
Only through the sequence and mass in the batch certificate of analysis (COA), confirmed by mass spectrometry and HPLC. The legality of reagents and the rules for trading in them are covered on the Law and Safety page.